{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:01:41Z","timestamp":1792152101694,"version":"4.4.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,28]]},"abstract":"<jats:p>Two articles this week focus on Erdheim-Chester disease (ECD), a rare histiocytosis that mainly affects adults. Clonal somatic mutations primarily involving proteins in the BRAF and MPAK pathways have established ECD as a myeloid neoplasm, with targeted therapies now available for patients. In the first paper, an international panel presents new consensus recommendations for evaluation and treatment of ECD. In the second paper, Pegoraro and colleagues present long-term outcomes of patients with ECD treated with sirolimus, with responses in patients both with and without BRAF mutations.<\/jats:p>","DOI":"10.1182\/blood.2019004478","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T17:15:33Z","timestamp":1587057333000},"page":"1994-1997","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Long-term follow-up of mTOR inhibition for Erdheim-Chester disease"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-5744","authenticated-orcid":false,"given":"Francesco","family":"Pegoraro","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Firenze, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Maniscalco","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Firenze, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-1952","authenticated-orcid":false,"given":"Francesco","family":"Peyronel","sequence":"first","affiliation":[{"name":"Nephrology Unit, University Hospital, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-920X","authenticated-orcid":false,"given":"Pieter J.","family":"Westenend","sequence":"first","affiliation":[{"name":"Department of Pathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadek R.","family":"Hendriksz","sequence":"first","affiliation":[{"name":"Department of Radiology, Albert Schweitzer Hospital, Dutch National Center of expertise for retroperitoneal fibrosis, Dordrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Roperto","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, Meyer Children\u2019s Hospital, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro A.","family":"Palumbo","sequence":"first","affiliation":[{"name":"Department of Radiology, University Hospital, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-9812","authenticated-orcid":false,"given":"Elena","family":"Sieni","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Meyer Children\u2019s Hospital, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1774-8088","authenticated-orcid":false,"given":"Paola","family":"Romagnani","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, Meyer Children\u2019s Hospital, Florence, Italy;"},{"name":"Department of Biomedical, Experimental and Clinical Sciences \u201cMario Serio,\" University of Firenze, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F. H.","family":"van Bommel","sequence":"first","affiliation":[{"name":"Department of Nephrology, Albert Schweitzer Hospital, Dutch National Center of Expertise for Retroperitoneal Fibrosis, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Vaglio","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, Meyer Children\u2019s Hospital, Florence, Italy;"},{"name":"Department of Biomedical, Experimental and Clinical Sciences \u201cMario Serio,\" University of Firenze, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2020052811205066700_B1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020052811205066700_B2","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S1470-2045(17)30031-1","article-title":"Histiocytoses: emerging neoplasia behind inflammation","volume":"18","author":"Haroche","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020052811205066700_B3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","article-title":"Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation","volume":"124","author":"Hervier","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020052811205066700_B4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2016-12-757823","article-title":"Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults","volume":"130","author":"Milne","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020052811205066700_B5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2016-12-757377","article-title":"Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem\/progenitor cells","volume":"130","author":"Durham","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020052811205066700_B6","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1002\/art.22280","article-title":"Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis","volume":"54","author":"Stoppacciaro","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2020052811205066700_B7","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2010-10-313510","article-title":"Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020052811205066700_B8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","article-title":"Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease","volume":"124","author":"Diamond","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020052811205066700_B9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2017-07-795054","article-title":"Erdheim-Chester disease: the \u201ctargeted\u201d revolution","volume":"130","author":"Vaglio","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2020052811205066700_B10","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","article-title":"CNS involvement and treatment with interferon-\u03b1 are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2020052811205066700_B11","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020052811205066700_B12","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020052811205066700_B13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600\u2013mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7749","key":"2020052811205066700_B14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"11","key":"2020052811205066700_B15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2015-09-672667","article-title":"Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease","volume":"127","author":"Cohen-Aubart","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2020052811205066700_B16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2017-01-761718","article-title":"High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis","volume":"130","author":"Papo","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020052811205066700_B17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/14656566.2013.791677","article-title":"Evaluation of everolimus in renal cell cancer","volume":"14","author":"Amato","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2020052811205066700_B18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1586\/1744666X.2014.872562","article-title":"The pros and the cons of mTOR inhibitors in kidney transplantation","volume":"10","author":"Ponticelli","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"2020052811205066700_B19","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","article-title":"Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial","volume":"126","author":"Gianfreda","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020052811205066700_B20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/0284186X.2019.1589648","article-title":"Sirolimus monotherapy for Erdheim-Chester disease","volume":"58","author":"van Bommel","year":"2019","journal-title":"Acta Oncol"},{"issue":"20","key":"2020052811205066700_B21","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1182\/blood-2016-07-724815","article-title":"Cardiac involvement in Erdheim-Chester disease: an MRI study","volume":"128","author":"Gianfreda","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2020052811205066700_B22","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1161\/CIRCULATIONAHA.108.767467","article-title":"Pericarditis heralding Erdheim-Chester disease","volume":"118","author":"Vaglio","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"2020052811205066700_B23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"2020052811205066700_B24","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"1","key":"2020052811205066700_B25","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/NXI.0000000000000299","article-title":"Targeted treatment of brainstem neurohistiocytosis guided by urinary cell-free DNA","volume":"4","author":"Hunt","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/22\/1994\/1736017\/bloodbld2019004478r1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/22\/1994\/1736017\/bloodbld2019004478r1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T11:21:14Z","timestamp":1590664874000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/22\/1994\/454410\/Longterm-followup-of-mTOR-inhibition-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":25,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004478","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]}}}